Molecular pathways of angiogenesis inhibition

Sebastien P Tabruyn; Arjan W Griffioen

doi:10.1016/j.bbrc.2007.01.123

Molecular pathways of angiogenesis inhibition

Biochem Biophys Res Commun. 2007 Mar 30;355(1):1-5. doi: 10.1016/j.bbrc.2007.01.123. Epub 2007 Jan 30.

Authors

Sebastien P Tabruyn¹, Arjan W Griffioen

Affiliation

¹ Angiogenesis Laboratory, Department of Pathology, Research Institute for Growth and Development (GROW), University of Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.

PMID: 17276388
DOI: 10.1016/j.bbrc.2007.01.123

Abstract

A large body of evidence now demonstrates that angiostatic therapy represents a promising way to fight cancer. This research recently resulted in the approval of the first angiostatic agent for clinical treatment of cancer. Progress has been achieved in decrypting the cellular signaling in endothelial cells induced by angiostatic agents. These agents predominantly interfere with the molecular pathways involved in migration, proliferation and endothelial cell survival. In the current review, these pathways are discussed. A thorough understanding of the mechanism of action of angiostatic agents is required to develop efficient anti-tumor therapies.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Angiostatins / therapeutic use
Apoptosis / drug effects
Autoantigens / therapeutic use
Cell Cycle / drug effects
Cell Division / drug effects
Cell Survival / drug effects
Collagen Type IV / therapeutic use
Endostatins / therapeutic use
Humans
Matrix Metalloproteinase Inhibitors
Neovascularization, Pathologic / prevention & control*
Platelet Factor 4 / therapeutic use
Thrombospondin 1 / therapeutic use

Substances

Angiogenesis Inhibitors
Autoantigens
Collagen Type IV
Endostatins
Matrix Metalloproteinase Inhibitors
Thrombospondin 1
type IV collagen alpha3 chain
Platelet Factor 4
Angiostatins